EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Preclinical Models of Neuroendocrine Prostate Cancer

Alessia Cacciatore, Domenico Albino, Carlo V Catapano, Giuseppina M Carbone

Current Protocols · 2023-05 · 3 (5)

DOI: 10.1002/cpz1.742 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Protocols, online erschienen am 11.05.2023. Verfasst von Alessia Cacciatore und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona, Switzerland. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Foundation Nelia et Amadeo Barletta, Fondazione Ticinese Ricerca sul Cancro, Fondazione San Salvatore.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PCa) is the most common malignancy and the second leading cause of cancer‐related death amongst men in the United States. Neuroendocrine prostate cancer (NEPC) can either arise de novo or emerge as a consequence of therapy. De novo NEPC is rare, with an incidence of 20% of patients with metastatic castration‐resistant prostate cancer (CRPC) reported to progress to neuroendocrine (NE) differentiation. The emergence of treatment‐induced NEPC is linked to the increased therapeutic pressure, due to the broad application of androgen deprivation therapy (ADT) for PCa management and the development of novel more potent androgen receptor (AR) pathway inhibitors. NEPC is a high‐grade tumor type characterized by aggressive phenotype and clinical behavior. Patients affected by NEPC frequently develop visceral metastases and have a poor prognosis. The molecular mechanisms underlying the development and progression of NEPC are still poorly understood. Transcriptional and epigenetic reprogramming appears to be involved in NE progression. In this review, we aim to provide a comprehensive view of the available models for NEPC detailing their strengths and limitations. Moreover, we describe novel approaches to expand the repertoire of preclinical models to better study, prevent, or reverse NEPC. The integration of multiple preclinical models along with molecular and omics approaches will provide important insights to understand disease progression and to devise novel therapeutic strategies for the management of NEPC in the near future. © 2023 The Authors. Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1 : Generation of organoids starting from the prostate gland of a GEMM or a human PDX Basic Protocol 2 : Ex vivo tumor sphere formation

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsMaleHumansAndrogen AntagonistsProstateAndrogen Receptor Antagonists

Stichwörter der Autor:innen

genetically engineered mouse model (GEMM)neuroendocrine prostate cancer (NEPC)patient-derived xenografts (PDX)preclinical models

Substanzen

Androgen AntagonistsAndrogen Receptor Antagonists

Autor:innen und Institutionen

  • Institute of Oncology Research (IOR), Università della Svizzera Italiana (USI), Bellinzona, Switzerland.

Förderung

  • Foundation Nelia et Amadeo Barletta
  • Fondazione Ticinese Ricerca sul Cancro
  • Fondazione San Salvatore

Zitieren

APA

Cacciatore, A., Albino, D., Catapano, C. V., & Carbone, G. M. (2023). Preclinical Models of Neuroendocrine Prostate Cancer. Current Protocols, 3(5). https://doi.org/10.1002/cpz1.742

Vancouver

Cacciatore A, Albino D, Catapano CV, Carbone GM. Preclinical Models of Neuroendocrine Prostate Cancer. Current Protocols. 2023;3(5). doi:10.1002/cpz1.742

BibTeX
@article{Cacciatore2023,
  author = {Cacciatore, Alessia and Albino, Domenico and Catapano, Carlo V and Carbone, Giuseppina M},
  title = {Preclinical Models of Neuroendocrine Prostate Cancer},
  journal = {Current Protocols},
  year = {2023},
  volume = {3},
  number = {5},
  doi = {10.1002/cpz1.742}
}
Kostenlos starten →